

Lynne M Mofenson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3745262/publications.pdf>

Version: 2024-02-01

321
papers

22,950
citations

9264

74
h-index

10445

139
g-index

411
all docs

411
docs citations

411
times ranked

12262
citing authors

#	ARTICLE	IF	CITATIONS
1	Standardized Definitions of In Utero Human Immunodeficiency Virus and Antiretroviral Drug Exposure Among Children. <i>Clinical Infectious Diseases</i> , 2022, 75, 347-355.	5.8	6
2	Assessment of Clinical Outcomes Among Children and Adolescents Hospitalized With COVID-19 in 6 Sub-Saharan African Countries. <i>JAMA Pediatrics</i> , 2022, 176, e216436.	6.2	44
3	Growth and CD4 patterns of adolescents living with perinatally acquired HIV worldwide, a CIPHER cohort collaboration analysis. <i>Journal of the International AIDS Society</i> , 2022, 25, e25871.	3.0	8
4	The Need to Study Clinical Outcomes in Children and Adolescents With COVID-19 From Middle- and Low-Income Regions. <i>JAMA Pediatrics</i> , 2022, 176, 728.	6.2	1
5	What babies need: accelerating access to current and novel antiretroviral drugs in neonates through pharmacokinetic studies. <i>Lancet HIV</i> , 2022, 9, e649-e657.	4.7	5
6	Surveillance of ARV safety in pregnancy and breastfeeding: towards a new framework. <i>Journal of the International AIDS Society</i> , 2022, 25, .	3.0	8
7	Pregnancy and medicines: time for paradigm change. <i>Journal of the International AIDS Society</i> , 2022, 25, .	3.0	3
8	Clinical and population-based study design considerations to accelerate the investigation of new antiretrovirals during pregnancy. <i>Journal of the International AIDS Society</i> , 2022, 25, .	3.0	6
9	Characterising and managing paediatric SARS-CoV-2 infection: Learning about the virus in a global classroom. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2021, 110, 409-422.	1.5	2
10	Impact of postpartum tenofovir-based antiretroviral therapy on bone mineral density in breastfeeding women with HIV enrolled in a randomized clinical trial. <i>PLoS ONE</i> , 2021, 16, e0246272.	2.5	6
11	The Critical Need for Pooled Data on Coronavirus Disease 2019 in African Children: An AFREhealth Call for Action Through Multicountry Research Collaboration. <i>Clinical Infectious Diseases</i> , 2021, 73, 1913-1919.	5.8	14
12	Enhanced and Timely Investigation of ARVs for Use in Pregnant Women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 86, 607-615.	2.1	15
13	Adverse Pregnancy Outcomes Among HIV-positive Women in the Era of Universal Antiretroviral Therapy Remain Elevated Compared With HIV-negative Women. <i>Pediatric Infectious Disease Journal</i> , 2021, 40, 821-826.	2.0	13
14	Scaling Up Covid-19 Vaccination in Africa – Lessons from the HIV Pandemic. <i>New England Journal of Medicine</i> , 2021, 385, 196-198.	27.0	15
15	A randomized controlled trial evaluating the effects of a family-centered HIV care model on viral suppression and retention in care of HIV-positive children in Eswatini. <i>PLoS ONE</i> , 2021, 16, e0256256.	2.5	3
16	Ethically designing research to inform multidimensional, rapidly evolving policy decisions: Lessons learned from the PROMISE HIV Perinatal Prevention Trial. <i>Clinical Trials</i> , 2021, 18, 174077452110457.	1.6	1
17	Association of Maternal Viral Load and CD4 Count With Perinatal HIV-1 Transmission Risk During Breastfeeding in the PROMISE Postpartum Component. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 88, 206-213.	2.1	22
18	Treatment of COVID-19 in pregnant women: A systematic review and meta-analysis. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2021, 267, 120-128.	1.1	19

#	ARTICLE	IF	CITATIONS
19	Ending the evidence gap for pregnancy, HIV and co-infections: ethics guidance from the PHASES project. <i>Journal of the International AIDS Society</i> , 2021, 24, e25846.	3.0	16
20	Analysis of Pharmacovigilance Databases for Dolutegravir Safety in Pregnancy. <i>Clinical Infectious Diseases</i> , 2020, 70, 2599-2606.	5.8	13
21	Safety, Tolerability, and Pharmacokinetics of the Broadly Neutralizing Human Immunodeficiency Virus (HIV)-1 Monoclonal Antibody VRC01 in HIV-Exposed Newborn Infants. <i>Journal of Infectious Diseases</i> , 2020, 222, 628-636.	4.0	38
22	Emerging evidence from a systematic review of safety of pre-exposure prophylaxis for pregnant and postpartum women: where are we now and where are we heading?. <i>Journal of the International AIDS Society</i> , 2020, 23, e25426.	3.0	67
23	Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: A systematic literature review and network meta-analysis. <i>EClinicalMedicine</i> , 2020, 28, 100573.	7.1	54
24	Challenges in the Early Infant HIV Diagnosis and Treatment Cascade. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 84, S1-S4.	2.1	14
25	Defining gaps in pre-exposure prophylaxis delivery for pregnant and post-partum women in high-burden settings using an implementation science framework. <i>Lancet HIV</i> , 2020, 7, e582-e592.	4.7	44
26	“There are no more secrets”™: acceptability of a family-centered model of care for HIV positive children in Eswatini. <i>BMC Health Services Research</i> , 2020, 20, 951.	2.2	6
27	Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. <i>BMJ</i> , 2020, 370, m3320.	6.0	1,474
28	SARS-COV-2 Maternal-to-Child Transmission. <i>Pediatric Infectious Disease Journal</i> , 2020, 39, e263-e264.	2.0	4
29	Accelerating progress towards the elimination of mother-to-child transmission of HIV: a narrative review. <i>Journal of the International AIDS Society</i> , 2020, 23, e25571.	3.0	25
30	Clinical manifestations, prevalence, risk factors, outcomes, transmission, diagnosis and treatment of COVID-19 in pregnancy and postpartum: a living systematic review protocol. <i>BMJ Open</i> , 2020, 10, e041868.	1.9	39
31	A Framework for Coordination between Obstetric and Pediatric Providers in Public Health Emergencies: Lessons Learned from the Zika Outbreak in the United States, 2015 to 2017. <i>American Journal of Perinatology</i> , 2020, 37, 982-990.	1.4	1
32	More on Clinical Characteristics of Pregnant Women with Covid-19 in Wuhan, China. <i>New England Journal of Medicine</i> , 2020, 383, 696-697.	27.0	9
33	Outcomes of second-line antiretroviral therapy among children living with HIV: a global cohort analysis. <i>Journal of the International AIDS Society</i> , 2020, 23, e25477.	3.0	5
34	Clinical Characteristics and Outcomes of Patients Hospitalized for COVID-19 in Africa: Early Insights from the Democratic Republic of the Congo. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, 103, 2419-2428.	1.4	87
35	Effect of SARS-CoV-2 Infection in Pregnancy on Maternal and Neonatal Outcomes in Africa: An AFREhealth Call for Evidence through Multicountry Research Collaboration. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, , .	1.4	17
36	Optimizing responses to drug safety signals in pregnancy: the example of dolutegravir and neural tube defects. <i>Journal of the International AIDS Society</i> , 2019, 22, e25352.	3.0	25

#	ARTICLE	IF	CITATIONS
37	Intramuscular 17-hydroxyprogesterone caproate to prevent preterm birth among HIV-infected women in Zambia: study protocol of the IPOP randomized trial. <i>BMC Pregnancy and Childbirth</i> , 2019, 19, 81.	2.4	10
38	Incidence of switching to second-line antiretroviral therapy and associated factors in children with HIV: an international cohort collaboration. <i>Lancet HIV</i> , 2019, 6, e105-e115.	4.7	22
39	Decision Making in a Time of Uncertainty: Dolutegravir for Reproductive-Age Women. <i>Annals of Internal Medicine</i> , 2019, 170, 658.	3.9	4
40	Association of Antiretroviral Drug Regimen With Viral Suppression in HIV-positive Children on Antiretroviral Therapy in Eswatini. <i>Pediatric Infectious Disease Journal</i> , 2019, 38, 835-839.	2.0	11
41	Updates to the Spectrum/AIM model for estimating key HIV indicators at national and subnational levels. <i>Aids</i> , 2019, 33, S227-S234.	2.2	52
42	Prioritising the most needed paediatric antiretroviral formulations: the PADO4 list. <i>Lancet HIV</i> , 2019, 6, e623-e631.	4.7	27
43	Pharmacokinetics of Increased Nelfinavir Plasma Concentrations in Women During Pregnancy and Postpartum. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 386-393.	2.0	11
44	Time to First-Line ART Failure and Time to Second-Line ART Switch in the leDEA Pediatric Cohort. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 78, 221-230.	2.1	20
45	Risk of HIV Acquisition During Pregnancy and Postpartum: A Call for Action. <i>Journal of Infectious Diseases</i> , 2018, 218, 1-4.	4.0	17
46	Prevention of HIV-1 Transmission Through Breastfeeding: Efficacy and Safety of Maternal Antiretroviral Therapy Versus Infant Nevirapine Prophylaxis for Duration of Breastfeeding in HIV-1-Infected Women With High CD4 Cell Count (IMPAACT PROMISE): A Randomized, Open-Label, Clinical Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, 383-392.	2.1	115
47	Achieving Viral Suppression in 90% of People Living With Human Immunodeficiency Virus on Antiretroviral Therapy in Low- and Middle-Income Countries: Progress, Challenges, and Opportunities. <i>Clinical Infectious Diseases</i> , 2018, 66, 1487-1491.	5.8	41
48	Human Immunodeficiency Virus Antiretroviral Resistance and Transmission in Mother-Infant Pairs Enrolled in a Large Perinatal Study. <i>Clinical Infectious Diseases</i> , 2018, 66, 1770-1777.	5.8	17
49	Congenital Cytomegalovirus and HIV Perinatal Transmission. <i>Pediatric Infectious Disease Journal</i> , 2018, 37, 1016-1021.	2.0	26
50	Using Observational Data to Inform HIV Policy Change for Children and Youth. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 78, S22-S26.	2.1	7
51	Reply to Kojima and Klausner. <i>Clinical Infectious Diseases</i> , 2018, 67, 1469-1470.	5.8	1
52	Infectious Morbidity, Mortality and Nutrition in HIV-exposed, Uninfected, Formula-fed Infants. <i>Pediatric Infectious Disease Journal</i> , 2018, 37, 1271-1278.	2.0	22
53	In-utero ART exposure and the need for pharmacovigilance. <i>The Lancet Global Health</i> , 2018, 6, e716-e717.	6.3	14
54	Estimating the cost of diagnosing HIV at birth in Lesotho. <i>PLoS ONE</i> , 2018, 13, e0202420.	2.5	8

#	ARTICLE	IF	CITATIONS
55	Combined evaluation of sexually transmitted infections in HIV-infected pregnant women and infant HIV transmission. PLoS ONE, 2018, 13, e0189851.	2.5	42
56	The epidemiology of adolescents living with perinatally acquired HIV: A cross-region global cohort analysis. PLoS Medicine, 2018, 15, e1002514.	8.4	98
57	Piloting very early infant diagnosis of HIV in Lesotho: Acceptability and feasibility among mothers, health workers and laboratory personnel. PLoS ONE, 2018, 13, e0190874.	2.5	14
58	Antiretroviral Therapy for Perinatal HIV Prevention. New England Journal of Medicine, 2017, 376, 699-700.	27.0	5
59	Use of antiretrovirals in HIV-infected children in a tuberculosis prevention trial: IMPAACT P1041. International Journal of Tuberculosis and Lung Disease, 2017, 21, 38-45.	1.2	2
60	Preconception ART and preterm birth: real effect or selection bias? Authors' reply. Lancet HIV, the, 2017, 4, e150-e151.	4.7	2
61	Bone Age and Mineral Density Assessments Using Plain Roentgenograms in Tenofovir-exposed Infants in Malawi and Brazil Enrolled in HIV Prevention Trials Network 057. Pediatric Infectious Disease Journal, 2017, 36, 184-188.	2.0	3
62	Brief Report: Pediatric Cancer Burden and Treatment Resources Within the Pediatric IeDEA Consortium. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 76, 60-64.	2.1	3
63	Optimizing Research to Speed Up Availability of Pediatric Antiretroviral Drugs and Formulations. Clinical Infectious Diseases, 2017, 64, 1597-1603.	5.8	26
64	Cytomegalovirus Urinary Shedding in HIV-infected Pregnant Women and Congenital Cytomegalovirus Infection. Clinical Infectious Diseases, 2017, 65, 405-413.	5.8	21
65	Safety of Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Regimens in Pregnancy for HIV-Infected Women and Their Infants: A Systematic Review and Meta-Analysis. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 76, 1-12.	2.1	71
66	Preventing Human Immunodeficiency Virus Acquisition in Youth Generations at Risk. JAMA Pediatrics, 2017, 171, 829.	6.2	1
67	Improving estimates of children living with HIV from the Spectrum AIDS Impact Model. Aids, 2017, 31, S13-S22.	2.2	47
68	Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention. Obstetrical and Gynecological Survey, 2017, 72, 143-145.	0.4	0
69	Tenofovir disoproxil fumarate safety for women and their infants during pregnancy and breastfeeding. Aids, 2017, 31, 213-232.	2.2	93
70	Protecting the health of our AIDS-free generation. Aids, 2017, 31, 315-316.	2.2	9
71	Youth engagement in developing an implementation science research agenda on adolescent HIV testing and care linkages in sub-Saharan Africa. Aids, 2017, 31, S195-S201.	2.2	34
72	Timing of initiation of antiretroviral therapy and adverse pregnancy outcomes: a systematic review and meta-analysis. Lancet HIV, the, 2017, 4, e21-e30.	4.7	163

#	ARTICLE	IF	CITATIONS
73	Recent progress in immune-based interventions to prevent HIV transmission to children. <i>Journal of the International AIDS Society</i> , 2017, 20, e25038.	3.0	8
74	24-month HIV-free survival among infants born to HIV-positive women enrolled in Option B+ program in Kigali, Rwanda. <i>Medicine (United States)</i> , 2017, 96, e9445.	1.0	15
75	Update: Interim Guidance for the Diagnosis, Evaluation, and Management of Infants with Possible Congenital Zika Virus Infection – United States, October 2017. <i>Morbidity and Mortality Weekly Report</i> , 2017, 66, 1089-1099.	15.1	156
76	Assessing Very Early Infant Diagnosis Turnaround Times: Findings from a Birth Testing Pilot in Lesotho. <i>AIDS Research and Treatment</i> , 2017, 2017, 1-8.	0.7	22
77	Randomized trial of stopping or continuing ART among postpartum women with pre-ART CD4 ≤ 400 cells/mm ³ . <i>PLoS ONE</i> , 2017, 12, e0176009.	2.5	23
78	Conventional early infant diagnosis in Lesotho from specimen collection to results usage to manage patients: Where are the bottlenecks?. <i>PLoS ONE</i> , 2017, 12, e0184769.	2.5	13
79	Malaria in HIV-Infected Children Receiving HIV Protease-Inhibitor- Compared with Non-Nucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy, IMPAACT P1068s, Substudy to P1060. <i>PLoS ONE</i> , 2016, 11, e0165140.	2.5	11
80	Brief Report: APOL1 Renal Risk Variants Are Associated With Chronic Kidney Disease in Children and Youth With Perinatal HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 73, 63-68.	2.1	30
81	<i>Chlamydia trachomatis</i> and <i>Neisseria gonorrhoeae</i> in HIV-infected Pregnant Women and Adverse Infant Outcomes. <i>Pediatric Infectious Disease Journal</i> , 2016, 35, 894-900.	2.0	46
82	Nevirapine- Versus Lopinavir/Ritonavir-Based Antiretroviral Therapy in HIV-Infected Infants and Young Children: Long-term Follow-up of the IMPAACT P1060 Randomized Trial. <i>Clinical Infectious Diseases</i> , 2016, 63, 1113-1121.	5.8	41
83	Eliminating Pediatric HIV-1 Infection. <i>New England Journal of Medicine</i> , 2016, 375, 192-194.	27.0	7
84	Diagnosis of HIV Infection During Early Infancy: How Early Is Early Enough?. <i>Journal of Infectious Diseases</i> , 2016, 214, 1294-1296.	4.0	3
85	Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention. <i>New England Journal of Medicine</i> , 2016, 375, 1726-1737.	27.0	268
86	Creating Sustainable Collaborations for Implementation Science: The Case of the NIH-PEPFAR PMTCT Implementation Science Alliance. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 72, S102-S107.	2.1	8
87	Maternal Highly Active Antiretroviral Therapy and Child HIV-Free Survival in Malawi, 2004–2009. <i>Maternal and Child Health Journal</i> , 2016, 20, 542-549.	1.5	5
88	Antiretroviral Therapy and Adverse Pregnancy Outcome: The Elephant in the Room?. <i>Journal of Infectious Diseases</i> , 2016, 213, 1051-1054.	4.0	62
89	Toward Earlier Inclusion of Pregnant and Postpartum Women in Tuberculosis Drug Trials: Consensus Statements From an International Expert Panel. <i>Clinical Infectious Diseases</i> , 2016, 62, 761-769.	5.8	43
90	Challenges in the Elimination of Pediatric HIV-1 Infection. <i>New England Journal of Medicine</i> , 2016, 374, 761-770.	27.0	112

#	ARTICLE	IF	CITATIONS
91	Tenofovir Pre-exposure Prophylaxis for Pregnant and Breastfeeding Women at Risk of HIV Infection: The Time is Now. <i>PLoS Medicine</i> , 2016, 13, e1002133.	8.4	26
92	Early Combination Antiretroviral Therapy Limits Exposure to HIV-1 Replication and Cell-Associated HIV-1 DNA Levels in Infants. <i>PLoS ONE</i> , 2016, 11, e0154391.	2.5	31
93	Update: Interim Guidance for the Evaluation and Management of Infants with Possible Congenital Zika Virus Infection – United States, August 2016. <i>Morbidity and Mortality Weekly Report</i> , 2016, 65, 870-878.	15.1	111
94	Reducing CD4 Monitoring in Children on Antiretroviral Therapy With Virologic Suppression. <i>Pediatric Infectious Disease Journal</i> , 2015, 34, 1361-1364.	2.0	12
95	Chlamydia and Gonorrhea in HIV-Infected Pregnant Women and Infant HIV Transmission. <i>Sexually Transmitted Diseases</i> , 2015, 42, 554-565.	1.7	68
96	Pharmacokinetics of Once Versus Twice Daily Darunavir in Pregnant HIV-Infected Women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 70, 33-41.	2.1	41
97	Lower Newborn Bone Mineral Content Associated With Maternal Use of Tenofovir Disoproxil Fumarate During Pregnancy. <i>Clinical Infectious Diseases</i> , 2015, 61, 996-1003.	5.8	97
98	New Challenges in the Elimination of Pediatric HIV Infection: The Expanding Population of HIV-Affected but Uninfected Children. <i>Clinical Infectious Diseases</i> , 2015, 60, 1357-60.	5.8	35
99	Cardiac effects of in-utero exposure to antiretroviral therapy in HIV-uninfected children born to HIV-infected mothers. <i>Aids</i> , 2015, 29, 91-100.	2.2	28
100	Long-term Safety and Efficacy of Atazanavir-based Therapy in HIV-infected Infants, Children and Adolescents. <i>Pediatric Infectious Disease Journal</i> , 2015, 34, 162-167.	2.0	19
101	Syphilis in HIV-infected Mothers and Infants. <i>Pediatric Infectious Disease Journal</i> , 2015, 34, e52-e57.	2.0	53
102	Tuberculosis in Pediatric Antiretroviral Therapy Programs in Low- and Middle-Income Countries: Diagnosis and Screening Practices. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2015, 4, 30-38.	1.3	14
103	Safety of Pediatric HIV Elimination: The Growing Population of HIV- and Antiretroviral-Exposed but Uninfected Infants. <i>PLoS Medicine</i> , 2014, 11, e1001636.	8.4	26
104	HIV Monoclonal Antibodies: A New Opportunity to Further Reduce Mother-to-Child HIV Transmission. <i>PLoS Medicine</i> , 2014, 11, e1001616.	8.4	29
105	Raltegravir Pharmacokinetics in Neonates Following Maternal Dosing. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 67, 310-315.	2.1	38
106	Children born into families affected by HIV. <i>Aids</i> , 2014, 28, S241-S244.	2.2	12
107	Safety of Cotrimoxazole in Pregnancy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 66, 512-521.	2.1	28
108	A Multi-Disciplinary Approach to Implementation Science. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 67, S163-S167.	2.1	42

#	ARTICLE	IF	CITATIONS
109	Realization of an AIDS-Free Generation. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 339.	7.4	6
110	Safety of efavirenz in the first trimester of pregnancy. <i>Aids</i> , 2014, 28, S123-S131.	2.2	183
111	Predictors of Virologic and Clinical Response to Nevirapine versus Lopinavir/Ritonavir-based Antiretroviral Therapy in Young Children With and Without Prior Nevirapine Exposure for the Prevention of Mother-to-child HIV Transmission. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, 846-854.	2.0	16
112	Pharmacokinetics and Safety of Tenofovir in HIV-Infected Women During Labor and Their Infants During the First Week of Life. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 65, 33-41.	2.1	60
113	Efficacy and Safety of an Extended Nevirapine Regimen in Infants of Breastfeeding Mothers With HIV-1 Infection for Prevention of HIV-1 Transmission (HPTN 046). <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 65, 366-374.	2.1	24
114	Combination Antiretroviral Use and Preterm Birth. <i>Journal of Infectious Diseases</i> , 2013, 207, 612-621.	4.0	107
115	The challenges of success: adolescents with perinatal HIV infection. <i>Journal of the International AIDS Society</i> , 2013, 16, 18650.	3.0	90
116	Prevention of mother-to-child HIV transmission. <i>Current Opinion in HIV and AIDS</i> , 2013, 8, 443-446.	3.8	8
117	Pooled Individual Data Analysis of 5 Randomized Trials of Infant Nevirapine Prophylaxis to Prevent Breast-Milk HIV-1 Transmission. <i>Clinical Infectious Diseases</i> , 2013, 56, 131-139.	5.8	19
118	Infant Feeding and Transmission of Human Immunodeficiency Virus in the United States. <i>Pediatrics</i> , 2013, 131, 391-396.	2.1	60
119	Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. <i>Pediatric Infectious Disease Journal</i> , 2013, 32, i.	2.0	46
120	Outcomes of Antiretroviral Therapy in Children in Asia and Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 62, 208-219.	2.1	81
121	Impact of Maternal and Infant Antiretroviral Drug Regimens on Drug Resistance in HIV-infected Breastfeeding Infants. <i>Pediatric Infectious Disease Journal</i> , 2013, 32, e164-e169.	2.0	31
122	Cognitive Function and Neurodevelopmental Outcomes in HIV-infected Children Older Than 1 Year of Age Randomized to Early Versus Deferred Antiretroviral Therapy. <i>Pediatric Infectious Disease Journal</i> , 2013, 32, 501-508.	2.0	138
123	Tenofovir Treatment Duration Predicts Proteinuria in a Multiethnic United States Cohort of Children and Adolescents With Perinatal HIV-1 Infection. <i>Pediatric Infectious Disease Journal</i> , 2013, 32, 495-500.	2.0	44
124	Antibody Maturation and Viral Diversification in HIV-Infected Women. <i>PLoS ONE</i> , 2013, 8, e57350.	2.5	7
125	Estimates of peripartum and postnatal mother-to-child transmission probabilities of HIV for use in Spectrum and other population-based models. <i>Sexually Transmitted Infections</i> , 2012, 88, i44-i51.	1.9	51
126	World Health Organization Generic Protocol to Assess Drug-Resistant HIV Among Children < 18 Months of Age and Newly Diagnosed With HIV in Resource-Limited Countries. <i>Clinical Infectious Diseases</i> , 2012, 54, S254-S260.	5.8	17

#	ARTICLE	IF	CITATIONS
127	Infant Outcomes After Maternal Antiretroviral Exposure in Resource-Limited Settings. <i>Pediatrics</i> , 2012, 129, e1525-e1532.	2.1	15
128	Three Postpartum Antiretroviral Regimens to Prevent Intrapartum HIV Infection. <i>New England Journal of Medicine</i> , 2012, 366, 2368-2379.	27.0	189
129	Nevirapine versus Ritonavir-Boosted Lopinavir for HIV-Infected Children. <i>New England Journal of Medicine</i> , 2012, 366, 2380-2389.	27.0	172
130	Evaluation of Tuberculosis Diagnostics in Children: 1. Proposed Clinical Case Definitions for Classification of Intrathoracic Tuberculosis Disease. Consensus From an Expert Panel. <i>Journal of Infectious Diseases</i> , 2012, 205, S199-S208.	4.0	275
131	A Trigger-based Design for Evaluating the Safety of In Utero Antiretroviral Exposure in Uninfected Children of Human Immunodeficiency Virus-Infected Mothers. <i>American Journal of Epidemiology</i> , 2012, 175, 950-961.	3.4	36
132	Antiretrovirals in Pregnancy: A Note of Caution. <i>Journal of Infectious Diseases</i> , 2012, 206, 1639-1641.	4.0	22
133	Progress, Challenges, and New Opportunities for the Prevention of Mother-to-Child Transmission of HIV Under the US President's Emergency Plan for AIDS Relief. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 60, S78-S87.	2.1	59
134	Safety of tenofovir use during pregnancy. <i>Aids</i> , 2012, 26, 1151-1159.	2.2	118
135	Unresolved Antiretroviral Treatment Management Issues in HIV-Infected Children. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 59, 161-169.	2.1	24
136	Evaluation of Viral Load Thresholds for Predicting New World Health Organization Stage 3 and 4 Events in HIV-Infected Children Receiving Highly Active Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 60, 214-218.	2.1	4
137	Stavudine Concentrations in Women Receiving Postpartum Antiretroviral Treatment and Their Breastfeeding Infants. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 60, 462-465.	2.1	5
138	Programmatic Impact of the Evolution of WHO Pediatric Antiretroviral Treatment Guidelines for Resource-Limited Countries (Tukula Fenna Project, Uganda). <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 61, 522-525.	2.1	7
139	Three Postpartum Antiretroviral Regimens to Prevent Intrapartum HIV Infection. <i>Obstetrical and Gynecological Survey</i> , 2012, 67, 612-614.	0.4	0
140	Adherence to antiretroviral therapy during and after pregnancy in low-income, middle-income, and high-income countries. <i>Aids</i> , 2012, 26, 2039-2052.	2.2	382
141	Safety and effectiveness of efavirenz versus nevirapine-based regimens in resource-limited settings. <i>Aids</i> , 2012, 26, 639-641.	2.2	1
142	Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2012, 379, 221-228.	13.7	108
143	Nevirapine prophylaxis during breastfeeding – Authors' reply. <i>Lancet, The</i> , 2012, 379, 1788.	13.7	0
144	Early versus deferred antiretroviral therapy for children older than 1 year infected with HIV (PREDICT): a multicentre, randomised, open-label trial. <i>Lancet Infectious Diseases, The</i> , 2012, 12, 933-941.	9.1	78

#	ARTICLE	IF	CITATIONS
145	Prevention of mother-to-child transmission of HIV-1. , 2012, , 485-507.		0
146	First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial. <i>Lancet Infectious Diseases</i> , The, 2011, 11, 273-283.	9.1	123
147	Safety of efavirenz in the first trimester of pregnancy. <i>Aids</i> , 2011, 25, 2301-2304.	2.2	108
148	Nelfinavir and Lamivudine Pharmacokinetics During the First Two Weeks of Life. <i>Pediatric Infectious Disease Journal</i> , 2011, 30, 769-772.	2.0	36
149	Point-of-care Capillary Blood Lactate Measurements in Human Immunodeficiency Virus-uninfected Children With In Utero Exposure to Human Immunodeficiency Virus and Antiretroviral Medications. <i>Pediatric Infectious Disease Journal</i> , 2011, 30, 1069-1074.	2.0	11
150	Antiretroviral Drugs for Preventing Mother-to-Child Transmission of HIV: A Review of Potential Effects on HIV-Exposed but Uninfected Children. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 57, 290-296.	2.1	76
151	Postexposure Prophylaxis of Breastfeeding HIV-Exposed Infants With Antiretroviral Drugs to Age 14 Weeks: Updated Efficacy Results of the PEPi-Malawi Trial. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 57, 319-325.	2.1	36
152	Atazanavir and atazanavir/ritonavir pharmacokinetics in HIV-infected infants, children, and adolescents. <i>Aids</i> , 2011, 25, 1489-1496.	2.2	18
153	Initiation of Antiretroviral Treatment in Women After Delivery Can Induce Multiclass Drug Resistance in Breastfeeding HIV-Infected Infants. <i>Clinical Infectious Diseases</i> , 2011, 52, 1069-1076.	5.8	47
154	Adolescents and HIV Infection: The Pediatrician's Role in Promoting Routine Testing. <i>Pediatrics</i> , 2011, 128, 1023-1029.	2.1	101
155	Effects of Cessation of Breastfeeding in HIV-1-Exposed, Uninfected Children in Malawi. <i>Clinical Infectious Diseases</i> , 2011, 53, 388-395.	5.8	50
156	Birth defects among a cohort of infants born to HIV-infected women on antiretroviral medication. <i>Journal of Perinatal Medicine</i> , 2011, 39, 163-70.	1.4	35
157	Pharmacokinetics and Safety of Single-Dose Tenofovir Disoproxil Fumarate and Emtricitabine in HIV-1-Infected Pregnant Women and Their Infants. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 5914-5922.	3.2	53
158	Antiretroviral Treatment of US Children With Perinatally Acquired HIV Infection: Temporal Changes in Therapy Between 1991 and 2009 and Predictors of Immunologic and Virologic Outcomes. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 57, 165-173.	2.1	69
159	Analysis of nevirapine resistance in HIV-infected infants who received extended nevirapine or nevirapine/zidovudine prophylaxis. <i>Aids</i> , 2011, 25, 911-917.	2.2	18
160	Prevention of Mother-to-Child HIV-1 Transmission—Why We Still Need a Preventive HIV Immunization Strategy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 58, 359-362.	2.1	15
161	Potential Confounding of the Association Between Exposure to Nucleoside Analogues and Mitochondrial Dysfunction in HIV-Uninfected and Indeterminate Infants. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2010, 53, 154-157.	2.1	9
162	Addition of extended zidovudine to extended nevirapine prophylaxis reduces nevirapine resistance in infants who were HIV-infected in utero. <i>Aids</i> , 2010, 24, 381-386.	2.2	19

#	ARTICLE	IF	CITATIONS
163	Safety of efavirenz in first-trimester of pregnancy: a systematic review and meta-analysis of outcomes from observational cohorts. <i>Aids</i> , 2010, 24, 1461-1470.	2.2	94
164	Postnatal Human Immunodeficiency Virus-1 Transmission After Cessation of Infant Extended Antiretroviral Prophylaxis and Effect of Maternal Highly Active Antiretroviral Therapy. <i>Obstetrical and Gynecological Survey</i> , 2010, 65, 150-151.	0.4	0
165	Declines in Mortality Rates and Changes in Causes of Death in HIV-1-Infected Children During the HAART Era. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 53, 86-94.	2.1	249
166	Frequency of Gastroenteritis and Gastroenteritis-Associated Mortality With Early Weaning in HIV-1-Uninfected Children Born to HIV-Infected Women in Malawi. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 53, 6-13.	2.1	106
167	Antiretroviral drugs to prevent breastfeeding HIV transmission. <i>Antiviral Therapy</i> , 2010, 15, 537-553.	1.0	50
168	Viral Load Predicts New World Health Organization Stage 3 and 4 Events in HIV-Infected Children Receiving Highly Active Antiretroviral Therapy, Independent of CD4 T Lymphocyte Value. <i>Clinical Infectious Diseases</i> , 2010, 51, 1325-1333.	5.8	16
169	Prevention in Neglected Subpopulations: Prevention of Mother-to-Child Transmission of HIV Infection. <i>Clinical Infectious Diseases</i> , 2010, 50, S130-S148.	5.8	110
170	Neurodevelopment and In Utero Antiretroviral Exposure of HIV-Exposed Uninfected Infants. <i>Pediatrics</i> , 2010, 125, e250-e260.	2.1	77
171	Protecting the Next Generation â€” Eliminating Perinatal HIV-1 Infection. <i>New England Journal of Medicine</i> , 2010, 362, 2316-2318.	27.0	64
172	Antiretroviral Treatment for Children with Peripartum Nevirapine Exposure. <i>New England Journal of Medicine</i> , 2010, 363, 1510-1520.	27.0	210
173	Growing Up with HIV: Children, Adolescents, and Young Adults with Perinatally Acquired HIV Infection. <i>Annual Review of Medicine</i> , 2010, 61, 169-185.	12.2	195
174	Routine Newborn HIV Testing: An Idea Whose Time Has Come: In Reply. <i>Pediatrics</i> , 2009, 123, e363-e364.	2.1	0
175	Prevention of Breast Milk Transmission of HIV: The Time Is Now. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 52, 305-308.	2.1	12
176	Postnatal HIV-1 Transmission after Cessation of Infant Extended Antiretroviral Prophylaxis and Effect of Maternal Highly Active Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2009, 200, 1490-1497.	4.0	55
177	Evaluation and Management of the Infant Exposed to HIV-1 in the United States. <i>Pediatrics</i> , 2009, 123, 175-187.	2.1	45
178	Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. <i>MMWR Recommendations and Reports</i> , 2009, 58, 1-166.	61.1	90
179	Pharmacokinetics and Pharmacodynamics of Efavirenz and Nelfinavir in HIV-infected Children Participating in an Area-under-the-curve Controlled Trial. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 83, 300-306.	4.7	40
180	Early antiretroviral therapy of HIV-infected infants in resource-limited countries: possible, feasible, effective and challenging. <i>Aids</i> , 2008, 22, 1365-1368.	2.2	7

#	ARTICLE	IF	CITATIONS
181	Nevirapine Concentrations in Newborns Receiving an Extended Prophylactic Regimen. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2008, 47, 334-337.	2.1	47
182	Antiretroviral Prophylaxis to Reduce Breast Milk Transmission of HIV Type 1: New Data but Still Questions. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2008, 48, 237-240.	2.1	35
183	Pharmacokinetics and Safety of Nelfinavir When Used in Combination with Zidovudine and Lamivudine in HIV-Infected Pregnant Women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353. <i>HIV Clinical Trials</i> , 2008, 9, 115-125.	2.0	43
184	Plasma Drug Concentrations and Virologic Evaluations after Stopping Treatment with Nonnucleoside Reverse Transcriptase Inhibitors in HIV Type 1-Infected Children. <i>Clinical Infectious Diseases</i> , 2008, 46, 1601-1608.	5.8	16
185	Extended Antiretroviral Prophylaxis to Reduce Breast-Milk HIV-1 Transmission. <i>New England Journal of Medicine</i> , 2008, 359, 119-129.	27.0	351
186	Total Lymphocyte Count: Not a Surrogate Marker for Risk of Death in HIV-Infected Ugandan Children. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2008, 49, 171-178.	2.1	3
187	Prevention of Mother-to-Child Transmission of HIV-1. , 2008, , 497-512.		0
188	Nevirapine concentrations in newborns receiving an extended prophylactic regimen. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2008, 47, 334-7.	2.1	14
189	Pharmacokinetics and Safety of Indinavir in Human Immunodeficiency Virus-Infected Pregnant Women. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 783-786.	3.2	75
190	Clinical Response and Tolerability to and Safety of Saquinavir with Low-Dose Ritonavir in Human Immunodeficiency Virus Type 1-Infected Mothers and Their Infants. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 2208-2210.	3.2	23
191	Human Immunodeficiency Virus, Mycobacterium Tuberculosis, and Pregnancy: A Deadly Combination. <i>Clinical Infectious Diseases</i> , 2007, 45, 250-253.	5.8	29
192	Diagnosis of HIV-1 Infection in Children Younger Than 18 Months in the United States. <i>Pediatrics</i> , 2007, 120, e1547-e1562.	2.1	106
193	Male Circumcision for Prevention of HIV and Other Sexually Transmitted Diseases. <i>Pediatrics</i> , 2007, 119, 821-822.	2.1	25
194	Baseline resistance to nucleoside reverse transcriptase inhibitors fails to predict virologic response to combination therapy in children (PACTG 338). <i>AIDS Research and Therapy</i> , 2007, 4, 2.	1.7	2
195	Pharmacokinetics of oral zidovudine administered during labour: a preliminary study. <i>HIV Medicine</i> , 2007, 8, 451-456.	2.2	11
196	Impact of GB virus type C infection on mother-to-child HIV transmission in the Women and Infants Transmission Study Cohort. <i>HIV Medicine</i> , 2007, 8, 561-567.	2.2	10
197	International recommendations on antiretroviral drugs for treatment of HIV-infected women and prevention of mother-to-child HIV transmission in resource-limited settings: 2006 update. <i>American Journal of Obstetrics and Gynecology</i> , 2007, 197, S42-S55.	1.3	59
198	Recommendations for human immunodeficiency virus screening, prophylaxis, and treatment for pregnant women in the United States. <i>American Journal of Obstetrics and Gynecology</i> , 2007, 197, S26-S32.	1.3	47

#	ARTICLE	IF	CITATIONS
199	In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected children. <i>Aids</i> , 2007, 21, 929-938.	2.2	121
200	Association of cord blood nevirapine concentration with reported timing of dose and HIV-1 transmission. <i>Aids</i> , 2006, 20, 637.	2.2	5
201	Cotrimoxazole Prophylaxis in HIV-Infected Pregnant Women: Only a First Step. <i>Journal of Infectious Diseases</i> , 2006, 194, 1478-1480.	4.0	3
202	A Behavioral and Cognitive Profile of Clinically Stable HIV-Infected Children. <i>Pediatrics</i> , 2006, 117, 763-770.	2.1	158
203	Effect of Perinatal Antiretroviral Drug Exposure on Hematologic Values in HIV-Uninfected Children: An Analysis of the Women and Infants Transmission Study. <i>Journal of Infectious Diseases</i> , 2006, 194, 1089-1097.	4.0	107
204	Effects of Polymorphisms of Chemokine Receptors on Neurodevelopment and the Onset of Encephalopathy in Children with Perinatal HIV-1 Infection. <i>Applied Neuropsychology</i> , 2006, 13, 180-189.	1.5	7
205	GB Virus C Infection in Children With Perinatal Human Immunodeficiency Virus Infection. <i>Pediatric Infectious Disease Journal</i> , 2005, 24, 417-422.	2.0	10
206	Risk Factors for In Utero and Intrapartum Transmission of HIV. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2005, 38, 87-95.	2.1	133
207	Initiating and changing antiretroviral therapy. , 2005, , 355-376.		0
208	Breast-Milk Shedding of Drug-Resistant HIV-1 Subtype C in Women Exposed to Single-Dose Nevirapine. <i>Journal of Infectious Diseases</i> , 2005, 192, 1260-1264.	4.0	50
209	Association of Selected Phenotypic Markers of Lymphocyte Activation and Differentiation with Perinatal Human Immunodeficiency Virus Transmission and Infant Infection. <i>Vaccine Journal</i> , 2005, 12, 622-631.	3.1	6
210	Immune Reconstitution after Receipt of Highly Active Antiretroviral Therapy in Children with Advanced or Progressive HIV Disease and Complete or Partial Viral Load Response. <i>Journal of Infectious Diseases</i> , 2005, 192, 296-302.	4.0	18
211	Treating Opportunistic Infections among HIV-Exposed and Infected Children: Recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2005, 40, S1-S84.	5.8	73
212	Safety and pharmacokinetics of nelfinavir coadministered with zidovudine and lamivudine in infants during the first 6 weeks of life. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2005, 39, 189-94.	2.1	9
213	Immune Parameters and Morbidity in Hard Drug and Human Immunodeficiency Virus-exposed but Uninfected Infants. <i>Pediatrics</i> , 2004, 113, 1260-1266.	2.1	11
214	Hepatitis C Prevalence in Children With Perinatal Human Immunodeficiency Virus Infection Enrolled in a Long-term Follow-up Protocol. <i>JAMA Pediatrics</i> , 2004, 158, 1007.	3.0	23
215	A Trial of Three Antiretroviral Regimens in HIV-1-Infected Children. <i>New England Journal of Medicine</i> , 2004, 350, 2471-2480.	27.0	145
216	Antimicrobial-Specific Cell-Mediated Immune Reconstitution in Children with Advanced Human Immunodeficiency Virus Infection Receiving Highly Active Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2004, 39, 107-114.	5.8	19

#	ARTICLE	IF	CITATIONS
217	Successes and Challenges in the Perinatal HIV-1 Epidemic in the United States as Illustrated by the HIV-1 Serosurvey of Childbearing Women. <i>JAMA Pediatrics</i> , 2004, 158, 422.	3.0	46
218	Maternal viral load and rate of disease progression among vertically HIV-1-infected children. <i>Aids</i> , 2004, 18, 99-108.	2.2	40
219	Pharmacokinetics and Safety of Stavudine in HIV-1 Infected Pregnant Women and Their Infants: Pediatric AIDS Clinical Trials Group Protocol 332. <i>Journal of Infectious Diseases</i> , 2004, 190, 2167-2174.	4.0	36
220	Pharmacokinetics of Saquinavir plus Low-Dose Ritonavir in Human Immunodeficiency Virus-Infected Pregnant Women. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 430-436.	3.2	107
221	Maternal toxicity and pregnancy complications in human immunodeficiency virus-1-infected women receiving antiretroviral therapy: PACTG 316. <i>American Journal of Obstetrics and Gynecology</i> , 2004, 190, 506-516.	1.3	97
222	Long Term Tolerability and Safety of Enfuvirtide for Human Immunodeficiency Virus 1-Infected Children. <i>Pediatric Infectious Disease Journal</i> , 2004, 23, 713-718.	2.0	49
223	The Impact of Race/Ethnicity on Mother-to-Child HIV Transmission in the United States in Pediatric AIDS Clinical Trials Group Protocol 316. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2004, 36, 800-807.	2.1	14
224	Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. <i>Lancet, The</i> , 2003, 362, 859-868.	13.7	476
225	Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis. <i>Lancet, The</i> , 2003, 362, 1605-1611.	13.7	218
226	Alternatives to HIV-1 RNA concentration and CD4 count to predict mortality in HIV-1-infected children in resource-poor settings. <i>Lancet, The</i> , 2003, 362, 1625-1627.	13.7	45
227	Advances in the prevention of vertical transmission of human immunodeficiency virus. <i>Seminars in Pediatric Infectious Diseases</i> , 2003, 14, 295-308.	1.7	63
228	Pharmacokinetics and tolerance of zidovudine in preterm infants. <i>Journal of Pediatrics</i> , 2003, 142, 47-52.	1.8	96
229	Tale of Two Epidemics—The Continuing Challenge of Preventing Mother-to-Child Transmission of Human Immunodeficiency Virus. <i>Journal of Infectious Diseases</i> , 2003, 187, 721-724.	4.0	37
230	Effect of Cessation of Zidovudine Prophylaxis to Reduce Vertical Transmission on Maternal HIV Disease Progression and Survival. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003, 32, 170-181.	2.1	51
231	Predose Infant Nevirapine Concentration With the Two-Dose Intrapartum Neonatal Nevirapine Regimen: Association With Timing of Maternal Intrapartum Nevirapine Dose. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003, 33, 153-156.	2.1	56
232	Performance Characteristics of HIV-1 Culture and HIV-1 DNA and RNA Amplification Assays for Early Diagnosis of Perinatal HIV-1 Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003, 34, 512-519.	2.1	89
233	Risk factors for Kaposi's sarcoma-associated herpesvirus infection among HIV-1-infected pregnant women in the USA. <i>Aids</i> , 2003, 17, 425-433.	2.2	32
234	Safety and Trough Concentrations of Nevirapine Prophylaxis Given Daily, Twice Weekly, or Weekly in Breast-Feeding Infants From Birth to 6 Months. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003, 34, 482-490.	2.1	59

#	ARTICLE	IF	CITATIONS
235	Progression of HIV Disease Among Women Following Delivery. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2003, 33, 585-593.	2.1	71
236	The Interface of Perinatal HIV Prevention, Antiretroviral Drug Resistance, and Antiretroviral Treatment: What Do We Really Know?. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2003, 34, 308-311.	2.1	22
237	Early neurodevelopmental markers predictive of mortality in infants infected with HIV-1. <i>Developmental Medicine and Child Neurology</i> , 2003, 45, 76-84.	2.1	26
238	Early neurodevelopmental markers predictive of mortality in infants infected with HIV-1. <i>Developmental Medicine and Child Neurology</i> , 2003, 45, .	2.1	2
239	Development of Resistance Mutations in Women Receiving Standard Antiretroviral Therapy Who Received Intrapartum Nevirapine to Prevent Perinatal Human Immunodeficiency Virus Type 1 Transmission: A Substudy of Pediatric AIDS Clinical Trials Group Protocol 316. <i>Journal of Infectious Diseases</i> , 2002, 186, 181-188.	4.0	117
240	Antiretroviral Prophylaxis of Perinatal HIV-1 Transmission and the Potential Impact of Antiretroviral Resistance. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2002, 30, 216-229.	2.1	47
241	Combination Antiretroviral Strategies for the Treatment of Pregnant HIV-1-Infected Women and Prevention of Perinatal HIV-1 Transmission. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2002, 29, 484-494.	2.1	553
242	Antiretroviral Therapy during Pregnancy and the Risk of an Adverse Outcome. <i>New England Journal of Medicine</i> , 2002, 346, 1863-1870.	27.0	356
243	Osteonecrosis of the Hip (Legg-Calve-Perthes Disease) in Human Immunodeficiency Virus-Infected Children. <i>Pediatrics</i> , 2002, 109, e74-e74.	2.1	40
244	Safety of Antiretroviral Prophylaxis of Perinatal Transmission for HIV-Infected Pregnant Women and Their Infants. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2002, 30, 200-215.	2.1	86
245	Combination Antiretroviral Strategies for the Treatment of Pregnant HIV-1-Infected Women and Prevention of Perinatal HIV-1 Transmission. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2002, 29, 484-494.	2.1	763
246	Concentrations of protease inhibitors in cord blood after in utero exposure. <i>Pediatric Infectious Disease Journal</i> , 2002, 21, 835-838.	2.0	69
247	Safety and antiretroviral activity of chronic subcutaneous administration of T-20 in human immunodeficiency virus 1-infected children. <i>Pediatric Infectious Disease Journal</i> , 2002, 21, 653-659.	2.0	46
248	Two-Dose Intrapartum/Newborn Nevirapine and Standard Antiretroviral Therapy to Reduce Perinatal HIV Transmission<SUBTITLE>A Randomized Trial</SUBTITLE>. <i>JAMA - Journal of the American Medical Association</i> , 2002, 288, 189.	7.4	317
249	Growth in Human Immunodeficiency Virus-Infected Children Receiving Ritonavir-Containing Antiretroviral Therapy. <i>JAMA Pediatrics</i> , 2002, 156, 497.	3.0	38
250	Stavudine, nevirapine and ritonavir in stable antiretroviral therapy-experienced children with human immunodeficiency virus infection. <i>Pediatric Infectious Disease Journal</i> , 2002, 21, 119-125.	2.0	12
251	U.S. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. <i>MMWR Recommendations and Reports</i> , 2002, 51, 1-38; quiz CE1-4.	61.1	97
252	Duration of ruptured membranes and vertical transmission of HIV-1: a meta-analysis from 15 prospective cohort studies. <i>Aids</i> , 2001, 15, 357-368.	2.2	119

#	ARTICLE	IF	CITATIONS
253	Pharmacokinetics of Saquinavir-SGC in HIV-Infected Pregnant Women. <i>HIV Clinical Trials</i> , 2001, 2, 460-465.	2.0	49
254	Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). <i>Aids</i> , 2001, 15, 1951-1957.	2.2	368
255	Population pharmacokinetics of dapsone in children with human immunodeficiency virus infection. <i>Clinical Pharmacology and Therapeutics</i> , 2001, 70, 24-32.	4.7	8
256	Human Immunodeficiency Virus Type 1 (HIV-1) gp120-Specific Antibodies in Neonates Receiving an HIV-1 Recombinant gp120 Vaccine. <i>Journal of Infectious Diseases</i> , 2001, 184, 1331-1335.	4.0	57
257	Adolescents and Human Immunodeficiency Virus Infection: The Role of the Pediatrician in Prevention and Intervention. <i>Pediatrics</i> , 2001, 107, 188-190.	2.1	46
258	Perinatal Transmission of Human Immunodeficiency Virus Type 1 by Pregnant Women with RNA Virus Loads < 1000 Copies/mL. <i>Journal of Infectious Diseases</i> , 2001, 183, 539-545.	4.0	356
259	Safety of 2 Recombinant Human Immunodeficiency Virus Type 1 (HIV-1) Envelope Vaccines in Neonates Born to HIV-1-Infected Women. <i>Clinical Infectious Diseases</i> , 2001, 32, 801-807.	5.8	73
260	Pharmacokinetics of nelfinavir in human immunodeficiency virus-infected infants. <i>Pediatric Infectious Disease Journal</i> , 2001, 20, 746-751.	2.0	33
261	Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission. <i>Aids</i> , 2000, 14, F111-F115.	2.2	180
262	Quantification of human immunodeficiency virus type 1 p24 antigen and antibody rivals human immunodeficiency virus type 1 RNA and CD4+ enumeration for prognosis. <i>Pediatric Infectious Disease Journal</i> , 2000, 19, 544-551.	2.0	13
263	Risk factors for preterm birth, low birth weight, and intrauterine growth retardation in infants born to HIV-infected pregnant women receiving zidovudine. <i>Aids</i> , 2000, 14, 1389-1399.	2.2	67
264	Maternal and Infant Factors Predicting Disease Progression in Human Immunodeficiency Virus Type 1-Infected Infants. <i>Pediatrics</i> , 2000, 105, e8-e8.	2.1	82
265	Perinatal Exposure to Zidovudine - Benefits and Risks. <i>New England Journal of Medicine</i> , 2000, 343, 803-805.	27.0	37
266	Patterns of Plasma Human Immunodeficiency Virus Type 1 RNA Response to Highly Active Antiretroviral Therapy in Infected Children. <i>Journal of Infectious Diseases</i> , 2000, 182, 1769-1773.	4.0	31
267	Use of Human Immunodeficiency Virus (HIV) Human Hyperimmune Immunoglobulin in HIV Type 1-Infected Children (Pediatric AIDS Clinical Trials Group Protocol 273). <i>Journal of Infectious Diseases</i> , 2000, 181, 548-554.	4.0	30
268	Human Immunodeficiency Virus (HIV) Type 1 Antibodies in Perinatal HIV-1 Infection: Association with Human HIV-1 Transmission, Infection, and Disease Progression. <i>Journal of Infectious Diseases</i> , 2000, 182, 1243-1246.	4.0	16
269	Lymphoproliferative Responses to Recombinant HIV-1 Envelope Antigens in Neonates and Infants Receiving gp120 Vaccines. <i>Journal of Infectious Diseases</i> , 2000, 181, 890-896.	4.0	54
270	Advances and research directions in the prevention of mother-to-child HIV-1 transmission. <i>Lancet</i> , The, 2000, 355, 2237-2244.	13.7	203

#	ARTICLE	IF	CITATIONS
271	Measles Immunization in HIV-Infected Children. <i>Pediatrics</i> , 1999, 103, 1057-1060.	2.1	39
272	Combination Therapy With Stavudine (d4T) Plus Didanosine (ddl) in Children With Human Immunodeficiency Virus Infection. <i>Pediatrics</i> , 1999, 103, e62-e62.	2.1	19
273	Lack of Tumors in Infants With Perinatal HIV-1 Exposure and Fetal/Neonatal Exposure to Zidovudine. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1999, 20, 463-467.	0.3	107
274	Risk Factors for Perinatal Transmission of Human Immunodeficiency Virus Type 1 in Women Treated with Zidovudine. <i>New England Journal of Medicine</i> , 1999, 341, 385-393.	27.0	517
275	Combination Therapy with Efavirenz, Nelfinavir, and Nucleoside Reverse-Transcriptase Inhibitors in Children Infected with Human Immunodeficiency Virus Type 1. <i>New England Journal of Medicine</i> , 1999, 341, 1874-1881.	27.0	228
276	Planning for Children Whose Parents Are Dying of HIV/AIDS. <i>Pediatrics</i> , 1999, 103, 509-511.	2.1	25
277	Efficacy of Zidovudine and Human Immunodeficiency Virus (HIV) Hyperimmune Immunoglobulin for Reducing Perinatal HIV Transmission from HIV-Infected Women with Advanced Disease: Results of Pediatric AIDS Clinical Trials Group Protocol 185. <i>Journal of Infectious Diseases</i> , 1999, 179, 567-575.	4.0	156
278	Can Perinatal HIV Infection Be Eliminated in the United States?. <i>JAMA - Journal of the American Medical Association</i> , 1999, 282, 577.	7.4	46
279	Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. <i>Lancet</i> , The, 1999, 354, 795-802.	13.7	1,341
280	Short-course zidovudine for prevention of perinatal infection. <i>Lancet</i> , The, 1999, 353, 766-767.	13.7	53
281	Paediatric HIV-1 infection. <i>Lancet</i> , The, 1999, 354, S111-S116.	13.7	36
282	Disclosure of Illness Status to Children and Adolescents With HIV Infection. <i>Pediatrics</i> , 1999, 103, 164-166.	2.1	214
283	A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). <i>Aids</i> , 1999, 13, 479-486.	2.2	190
284	Lack of Long-term Effects of In Utero Exposure to Zidovudine Among Uninfected Children Born to HIV-Infected Women. <i>JAMA - Journal of the American Medical Association</i> , 1999, 281, 151.	7.4	303
285	Serum HIV-1 p24 antibody, HIV-1 RNA copy number and CD4 lymphocyte percentage are independently associated with risk of mortality in HIV-1-infected children. <i>Aids</i> , 1999, 13, 31-39.	2.2	37
286	Serum vitamin A concentrations in a North American cohort of human immunodeficiency virus type 1-infected children. <i>Pediatric Infectious Disease Journal</i> , 1999, 18, 134-142.	2.0	13
287	Toxicity and efficacy of daily vs. weekly dapsone for prevention of <i>Pneumocystis carinii</i> pneumonia in children infected with human immunodeficiency virus. <i>Pediatric Infectious Disease Journal</i> , 1999, 18, 432-439.	2.0	24
288	Pharmacokinetics of Dapsone Administered Daily and Weekly in Human Immunodeficiency Virus-Infected Children. <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 2586-2591.	3.2	14

#	ARTICLE	IF	CITATIONS
289	Dynamics of Human Immunodeficiency Virus Type 1 Replication in Vertically Infected Infants. <i>Journal of Virology</i> , 1999, 73, 362-367.	3.4	78
290	Population Pharmacokinetics of Dapsone in HIV-Infected Children. <i>Pediatric Research</i> , 1999, 45, 168A-168A.	2.3	1
291	A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naïve HIV-1 infection. <i>Journal of Pediatrics</i> , 1998, 133, 500-508.	1.8	108
292	ANTIRETROVIRAL THERAPY AND INTERRUPTION OF HIV PERINATAL TRANSMISSION. <i>Immunology and Allergy Clinics of North America</i> , 1998, 18, 441-463.	1.9	13
293	Perinatal Transmission of HIV in Women Receiving Zidovudine. <i>JAMA - Journal of the American Medical Association</i> , 1998, 280, 569.	7.4	4
294	RIFABUTIN. <i>Pediatric Infectious Disease Journal</i> , 1998, 17, 71-72.	2.0	4
295	Characteristics of acute pneumonia in human immunodeficiency virus-infected children and association with long term mortality risk. <i>Pediatric Infectious Disease Journal</i> , 1998, 17, 872-880.	2.0	29
296	Surveillance of Pediatric HIV Infection. <i>Pediatrics</i> , 1998, 101, 315-319.	2.1	11
297	Viral Load and Disease Progression in Infants Infected with Human Immunodeficiency Virus Type 1. <i>New England Journal of Medicine</i> , 1997, 336, 1337-1342.	27.0	524
298	The Relationship between Serum Human Immunodeficiency Virus Type 1 (HIV-1) RNA Level, CD4 Lymphocyte Percent, and Long-Term Mortality Risk in HIV-1-Infected Children. <i>Journal of Infectious Diseases</i> , 1997, 175, 1029-1038.	4.0	251
299	Evaluation and Medical Treatment of the HIV-Exposed Infant. <i>Pediatrics</i> , 1997, 99, 909-917.	2.1	45
300	Evaluation of Pharmacokinetics, Safety, Tolerance, and Activity of Combination of Zalcitabine and Zidovudine in Stable, Zidovudine-Treated Pediatric Patients with Human Immunodeficiency Virus Infection. <i>Journal of Infectious Diseases</i> , 1997, 175, 1039-1050.	4.0	28
301	MOTHER-CHILD HIV-1 TRANSMISSION. <i>Obstetrics and Gynecology Clinics of North America</i> , 1997, 24, 759-784.	1.9	79
302	Elevated CD8+DR+ Lymphocytes in HIV-Exposed Infants With Early Positive HIV Cultures. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1997, 15, 204-210.	0.3	18
303	Association of maternal drug use during pregnancy with maternal HIV culture positivity and perinatal HIV transmission. <i>Aids</i> , 1996, 10, 273-282.	2.2	169
304	Obstetrical Factors and the Transmission of Human Immunodeficiency Virus Type 1 from Mother to Child. <i>New England Journal of Medicine</i> , 1996, 334, 1617-1623.	27.0	427
305	The Role of Antiretroviral Therapy in the Management of HIV Infection in Women. <i>Clinical Obstetrics and Gynecology</i> , 1996, 39, 361-385.	1.1	4
306	A critical review of studies evaluating the relationship of mode of delivery to perinatal transmission of human immunodeficiency virus. <i>Pediatric Infectious Disease Journal</i> , 1995, 14, 169-177.	2.0	44

#	ARTICLE	IF	CITATIONS
307	Zidovudine for the reduction of perinatal human immunodeficiency virus transmission. <i>Pediatric Infectious Disease Journal</i> , 1995, 14, 536-541.	2.0	57
308	Prophylactic Immune Globulin in Children with HIV Disease. <i>New England Journal of Medicine</i> , 1995, 332, 750-752.	27.0	3
309	Sinusitis in Children Infected with Human Immunodeficiency Virus: Clinical Characteristics, Risk Factors, and Prophylaxis. <i>Clinical Infectious Diseases</i> , 1995, 21, 1175-1181.	5.8	29
310	The role of obstetric interventions in the prevention of pediatric human immunodeficiency virus infection. <i>American Journal of Obstetrics and Gynecology</i> , 1994, 171, 1167-1175.	1.3	33
311	Prevention of Infections in Children with Human Immunodeficiency Virus Infection. <i>BioDrugs</i> , 1994, 1, 258-270.	0.7	1
312	Crossover of placebo patients to intravenous immunoglobulin confirms efficacy for prophylaxis of bacterial infections and reduction of hospitalizations in human immunodeficiency virus-infected children. <i>Pediatric Infectious Disease</i> , 1994, 13, 477-484.	0.8	30
313	Maternal and pediatric AIDS in the United States: the current situation and future research directions. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 1994, 83, 106-110.	1.5	16
314	Immunologic Targets of HIV Infection: T Cells. <i>Annals of the New York Academy of Sciences</i> , 1993, 693, 35-51.	3.8	24
315	Maternal Drug Use in Perinatal HIV Studies: The Women and Infants Transmission Study. <i>Annals of the New York Academy of Sciences</i> , 1993, 693, 245-248.	3.8	20
316	Intravenous Immune Globulin for the Prevention of Infections in Children with Symptomatic Human Immunodeficiency Virus Infection. <i>Pediatric Research</i> , 1993, 33, S80-S89.	2.3	23
317	Prophylactic Intravenous Immunoglobulin in HIV-Infected Children With CD4+ Counts of 0.20 \bar{A} –109/L or More. <i>JAMA - Journal of the American Medical Association</i> , 1992, 268, 483.	7.4	57
318	Human Immunodeficiency Virus Infection in Pregnant Women Under Care at AIDS Clinical Trials Centers in the United States. <i>Obstetrics and Gynecology</i> , 1992, 79, 364-368.	2.4	16
319	Perinatally acquired human immunodeficiency virus infection. <i>Pediatric Infectious Disease Journal</i> , 1992, 11, 941-945.	2.0	13
320	Passive immunization to prevent mother-infant transmission of human immunodeficiency virus. <i>Pediatric Infectious Disease Journal</i> , 1991, 10, 456-462.	2.0	18
321	Initiating and changing antiretroviral therapy. , 0, , 415-438.		0